{‘She has no qualifications’: this US scientific community girds for Dr. Høeg's role at the Food and Drug Administration.

As the United States continues making historic adjustments to its immunization schedules, an unexpected name has surfaced somewhat surprisingly: Høeg, a Danish American sports physician and public health researcher who initially gained attention by expressing skepticism about Covid shots throughout the global health crisis and has zeroed in on potential deaths following Covid vaccination in her brief time at the US Food and Drug Administration (FDA).

Proposed Overhauls to Pediatric Immunization Program

Health officials planned to announce major revisions to the pediatric vaccine schedule earlier this month, synchronizing the US with the Danish national calendar, according to reports – a significant shift that would place the US out of step with many the world with insufficient data for improved outcomes. The announcement has been delayed until the coming year.

Instead of the director of the vaccine center, Høeg is set to present at the meeting. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the office this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position may indicate a tighter collaboration between the drug and vaccine centers as Høeg and Prasad solidify control at the FDA – and it suggests a renewed priority upon dismantling long-standing immunizations at the FDA.

Dr. Høeg has often pushed for ending some pediatric immunization guidelines in the US in order to be more like Denmark, a society with universal health coverage and a population approximately the population of the state of Wisconsin.

To date statements, she has persisted in emphasizing on vaccines – typically the responsibility of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Questions Over Expertise

Høeg has no apparent track record in pharmaceutical research, approval processes or leadership, which has been standard for previous directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the agency head and CBER since spring.

“She appears not to have any of the qualifications” for leading the pharmaceutical oversight division, stated Jonathan Howard. “She’s never run a scientific study. She has no expertise in leading a large organization. She lacks background in industry regulation.”

Previous commissioners of CBER would “grasp regulatory frameworks and the underlying principles of medication creation”, said Janet Woodcock. “Objectively, she has not acquired the type of experience that previous people who headed CBER have had.”

The drug center has an vast portfolio at the FDA, Woodcock pointed out.

“Everybody just zeroes in on the new drug program, but the generic program clears a multitude of off-brand pharmaceuticals. There is also a biologic copycat branch, OTC medication office and other areas, and every single one have to be supervised,” she noted. “The area you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

There is also, a substantial leadership element to the position, which manages more than 5,000 employees. “It’s a massive administrative position, if you do it right,” the former official said.

Agency Reaction and Controversial Programs

Regarding questions about Høeg’s credentials and whether this assignment signifies increased cooperation among FDA leaders on vaccines, a spokesperson stated that the “inquiries rely on flawed assumptions”.

“This background is consistent with the responsibilities of her role,” the official said, noting the period Høeg spent counseling the agency head on “drug safety and oversight research, including predictive safety algorithms and immunization monitoring”.

In her interim role, Høeg takes over the commissioner’s recently launched expedited review system, a contentious one-day medication authorization process that allegedly concerned her predecessors. “How are these drugs being selected for this fast-track system? Who is making the calls?” Dr. Howard said. “There is a lot of secrecy occurring at the regulatory body right now.”

In general, he remarked, “the FDA appears to be shifting towards laxer oversight of most medications, with the exception of vaccines.”

Established Track Record on Immunizations

Concerning immunizations, Dr. Høeg has a more documented, if troubling, history, critics said. She released a research paper using non-validated volunteer-provided data to determine the incidence of heart inflammation after Covid vaccination. She counseled the state of Florida top health official Joseph Ladapo, who was said to have modified findings to suggest Covid vaccines are pose a greater threat than they are.

Part of her “desired changes” for the new federal leadership featured revising regulations for novel immunizations and halting “non-essential” vaccines, she said after the election on a online show. At the agency, Høeg has according to sources floated the idea of excluding teenage boys from receiving Covid vaccinations.

“She’s an complete ideologue who starts off with her conclusions and reverse-engineers to accommodate the science in a extremely disingenuous, untruthful way,” Dr. Howard said.

Taking Control and a “Push for Payback”

Dr. Høeg aligned with fellow dissenters, {like|